WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
The Union for International Cancer Control and Pfizer announce next phase of global grants initiative supporting metastatic breast cancer patients 09 March 2017
Ronald E. Blaylock elected to Pfizer's Board of Directors 24 February 2017
Relationship expert teams up with Pfizer to address intimacy and relationship issues for people living with chronic diseases 10 February 2017
Pfizer reports fourth-quarter and full-year 2016 results 31 January 2017
Pfizer announces expansion of ASPIRE awards program for 2017 to include $5.5M in funding for breast and hematologic cancers 14 December 2016
IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery 02 December 2016
Pfizer's Prevenar 13® receives approval for use in infants and children in China 02 November 2016
Pfizer awarded grant to evaluate vaccine to protect newborns against group B Streptococcus infection 19 October 2016
Pfizer decides remaining one company best positions company to maximize future value creation 26 September 2016
Pfizer launches new "Moodivator" app to help support, encourage and motivate people with depression 14 September 2016
Pfizer appoints chief scientific officer for neuroscience research 08 September 2016
Pfizer to acquire small molecule anti-infective business from AstraZeneca 24 August 2016
Pfizer announces publication of new analysis showing long-term therapy with VYNDAQEL (tafamidis) slowed progression of rare neurodegenerative disease 12 August 2016
Pfizer aims to become industry leader in gene therapy with acquisition of Bamboo Therapeutics, Inc. 02 August 2016
Pfizer receives World Health Organization prequalification for multi-dose vial presentation of Prevenar 13® 19 July 2016
Merck and Pfizer initiate Phase III trial to evaluate Avelumab as first-line treatment for ovarian cancer 07 July 2016
Pfizer completes acquisition of Anacor 24 June 2016
Help Pfizer change the future of healthy aging 21 June 2016
Pfizer presents promising data from next generation ALK/ROS1 inhibitor in advanced non-small cell lung cancer 06 June 2016
Merck and Pfizer to present Avelumab data in seven different cancers at ASCO annual meeting 19 May 2016
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Pfizer

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.